Vertex Pharmaceuticals Incorporated $VRTX Shares Acquired by Vanguard Personalized Indexing Management LLC

Posted by Stanley Muller on Jun 15th, 2026

Vanguard Personalized Indexing Management LLC lifted its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 5.9% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 39,165 shares of the pharmaceutical company’s stock after buying an additional 2,165 shares during the period. Vanguard Personalized Indexing Management LLC’s holdings in Vertex Pharmaceuticals were worth $17,756,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Danske Bank A S acquired a new stake in Vertex Pharmaceuticals during the 3rd quarter worth approximately $64,417,000. Mitsubishi UFJ Asset Management Co. Ltd. lifted its holdings in Vertex Pharmaceuticals by 3.8% during the 3rd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 544,978 shares of the pharmaceutical company’s stock worth $213,435,000 after buying an additional 20,053 shares in the last quarter. Legacy Capital Group California Inc. acquired a new stake in Vertex Pharmaceuticals during the 3rd quarter worth approximately $956,000. Victory Capital Management Inc. lifted its holdings in Vertex Pharmaceuticals by 4.3% during the 3rd quarter. Victory Capital Management Inc. now owns 2,247,566 shares of the pharmaceutical company’s stock worth $880,237,000 after buying an additional 92,402 shares in the last quarter. Finally, Nordea Investment Management AB lifted its holdings in Vertex Pharmaceuticals by 23.8% during the 4th quarter. Nordea Investment Management AB now owns 447,169 shares of the pharmaceutical company’s stock worth $202,612,000 after buying an additional 86,084 shares in the last quarter. Institutional investors and hedge funds own 90.96% of the company’s stock.

More Vertex Pharmaceuticals News

Here are the key news stories impacting Vertex Pharmaceuticals this week:

Positive Sentiment: Vertex received bullish attention from market commentary highlighting that Wall Street remains interested in the stock despite a bearish “death cross” technical setup, suggesting investors are focusing more on the company’s fundamentals than the chart pattern. Article Title
Positive Sentiment: The company announced new CASGEVY data at the European Hematology Association Congress, including the first European presentation of results in children ages 5–11 and additional global regulatory submissions, which could support longer-term growth for the gene-editing therapy. Article Title
Positive Sentiment: Analysts and media coverage have been broadly upbeat on Vertex, including pieces describing it as a favored healthcare stock and a stock some investors view as attractive to buy now, reinforcing confidence in the name. Article Title
Neutral Sentiment: Erste Group slightly lowered its FY2027 EPS estimate for Vertex to $19.24 from $19.36, a small revision that may not materially change the long-term outlook but is a minor headwind for sentiment. Article Title
Negative Sentiment: The stock has also experienced a recent pullback in some sessions, reflecting normal volatility and some profit-taking even as the broader narrative remains constructive. Article Title

Vertex Pharmaceuticals Stock Performance

Shares of Vertex Pharmaceuticals stock opened at $444.92 on Monday. Vertex Pharmaceuticals Incorporated has a 1 year low of $362.50 and a 1 year high of $507.92. The company has a market capitalization of $112.92 billion, a P/E ratio of 26.39, a PEG ratio of 1.90 and a beta of 0.30. The company’s fifty day moving average is $437.14 and its two-hundred day moving average is $452.53.

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) last issued its earnings results on Monday, May 4th. The pharmaceutical company reported $4.47 earnings per share for the quarter, beating the consensus estimate of $4.24 by $0.23. The business had revenue of $2.99 billion for the quarter, compared to the consensus estimate of $2.99 billion. Vertex Pharmaceuticals had a net margin of 35.51% and a return on equity of 23.86%. The business’s quarterly revenue was up 8.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $4.06 earnings per share. As a group, equities analysts expect that Vertex Pharmaceuticals Incorporated will post 17.02 earnings per share for the current year.

Analyst Upgrades and Downgrades

VRTX has been the topic of a number of research reports. Citigroup increased their target price on shares of Vertex Pharmaceuticals from $575.00 to $585.00 and gave the stock a “buy” rating in a report on Tuesday, March 10th. Morgan Stanley increased their price objective on shares of Vertex Pharmaceuticals from $612.00 to $616.00 and gave the company an “overweight” rating in a research report on Tuesday, May 5th. Maxim Group raised shares of Vertex Pharmaceuticals from a “hold” rating to a “buy” rating and set a $575.00 price objective on the stock in a research report on Wednesday, March 18th. Bank of America increased their price objective on shares of Vertex Pharmaceuticals from $571.00 to $598.00 and gave the company a “buy” rating in a research report on Tuesday, March 10th. Finally, Sanford C. Bernstein dropped their price objective on shares of Vertex Pharmaceuticals from $577.00 to $572.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 5th. Twenty-two equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, Vertex Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $555.91.

Get Our Latest Research Report on Vertex Pharmaceuticals

Insider Buying and Selling

In other Vertex Pharmaceuticals news, EVP Joy Liu sold 1,104 shares of Vertex Pharmaceuticals stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $425.02, for a total transaction of $469,222.08. Following the completion of the transaction, the executive vice president owned 20,729 shares in the company, valued at approximately $8,810,239.58. The trade was a 5.06% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CMO Carmen Bozic sold 1,745 shares of Vertex Pharmaceuticals stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $450.00, for a total transaction of $785,250.00. Following the transaction, the chief marketing officer owned 21,015 shares of the company’s stock, valued at approximately $9,456,750. The trade was a 7.67% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 11,133 shares of company stock valued at $4,973,106. Corporate insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Company Profile

(Free Report)

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.